Blau Farmacêutica First Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag

Blau Farmacêutica (BVMF:BLAU3) First Quarter 2025 Results

Key Financial Results

• Revenue: R$373.0m (up 3.7% from 1Q 2024).
• Net income: R$90.9m (up 117% from 1Q 2024).
• Profit margin: 24% (up from 12% in 1Q 2024). The increase in margin was primarily driven by lower expenses.
• EPS: R$0.51 (up from R$0.23 in 1Q 2024).

We've discovered 1 warning sign about Blau Farmacêutica. View them for free.

All figures shown in the chart above are for the trailing 12 month (TTM) period

Blau Farmacêutica EPS Beats Expectations, Revenues Fall Short

Revenue missed analyst estimates by 1.6%. Earnings per share (EPS) exceeded analyst estimates by 58%.

Looking ahead, revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Global Biotechs industry.

Performance of the market in Brazil.

The company's shares are down 3.1% from a week ago.

Risk Analysis

It's still necessary to consider the ever-present spectre of investment risk. We've identified 1 warning sign with Blau Farmacêutica, and understanding it should be part of your investment process.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.